NL-OMON26657CompletedNot Applicable
A multi centre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair loss.
eids Universitair Medisch Centrum in Leiden0 sites260 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 260
Study Overview
Brief Summary
/A
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. Intravenous administered docetaxel regimes;
- •2. Age 18 years or more;
Exclusion Criteria
- •1. Boldness before the start of the study;
- •2. Heamatological malignancies with generalized haematogenic metastases (e.g. lymphoma, leukemia and multiple myeloma) and if in those conditions chemotherapy is given with a curative intent;
Investigators
Similar Trials
Completed
Not Applicable
Multicenter prospective study to assess the efficacy of macroscopic on-site quality evaluation during EUS-FNBJPRN-UMIN000036528Shizuoka Cancer Center108
Completed
Not Applicable
A multicentre study to determine the efficacy and patient acceptability of scalp cooling in the prevention of docetaxel-induced hair lossCancerISRCTN00283877eiden University Medical Centre (LUMC) (The Netherlands)260
Active, not recruiting
Not Applicable
Evaluation of biomarkers in BF treatmentlcerative colitisUlcerative colitisJPRN-jRCTs031210326Matsuoka Katsuyoshi20
Active, not recruiting
Not Applicable
A study conducted at several study sites with a human growth hormone in a liquid form and a concentration of 3.3. mg/mL that is produced by using genetic engineering techniques, to find out more about how efficacious it works and how safe its use is in pre-pubertal children of small stature who’s bodies do not produce sufficient amounts of own growth hormone.Small stature secondary to growth hormone insufficiency deficiencyEUCTR2015-002802-34-Outside-EU/EEASandoz SAS100
Completed
Phase 2
Multi-center study to evaluate the efficacy and to standardize RFA for early breast cancerEarly breast cancerJPRN-UMIN000008675ational Cancer Center Hospital372